Histological and Cytokine-Based Biomarkers in the Early Diagnosis of Cancer
Biomarker Berbasis Histologi dan Sitokin dalam Diagnosis Dini Kanker
DOI:
https://doi.org/10.21070/ijhsm.v2i2.93Keywords:
Histological Biomarkers, Cytokines, Early Cancer Diagnosis, IL-6, TNF-αAbstract
Background; Early detection of cancer significantly improves treatment outcomes and survival rates. Histological biomarkers, such as cellular atypia, mitotic figures, necrosis, and angiogenesis, play a crucial role in identifying malignancies. Cytokines like interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) are emerging as valuable biomarkers due to their involvement in cancer-related inflammation. Aims of the study; Evaluate the role of histological features and cytokine-based biomarkers, specifically interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), in the early diagnosis of cancer. Methodology; This case-control study, conducted from January to August 2024, included 150 cancer patients and 50 healthy controls. Inclusion criteria were adults aged 18-75 with a cancer diagnosis. Ethical approval was obtained. Tissue samples were processed for histology, and cytokine levels (IL-6, TNF-α) were measured using ELISA. Result; The results showed no significant differences in age and gender between patients and controls, but smoking, family history of cancer, and BMI were significantly higher in patients. Histological examinations revealed clear differences between cancerous and non-cancerous tissues. Cytokine levels were significantly elevated in patients, with strong correlations observed between cytokines and histological parameters. Finally, cytokines demonstrated high sensitivity and specificity, making them effective biomarkers for diagnosis. Conclusions; In conclusion, IL-6 and TNF-α are valuable biomarkers for cancer detection, demonstrating strong correlations with histological features. Their high sensitivity, specificity, and AUC support their potential in early diagnosis and prognosis of cancer.
Highlights:
- Early Detection: IL-6 and TNF-α show high sensitivity and specificity, making them valuable for early cancer diagnosis.
- Histological Correlation: Strong associations between cytokine levels and tumor features like necrosis and angiogenesis support their diagnostic relevance.
- Clinical Utility: The study reinforces cytokines as potential non-invasive biomarkers, aiding in early screening and prognosis of cancer.
References
[1] E. Safarzadeh, S. Sandoghchian, and B. Baradaran, “Herbal Medicine as Inducers of Apoptosis in Cancer Treatment,” Advanced Pharmaceutical Bulletin, vol. 4, pp. 421-427, 2014.
[2] D. S. Shewach and R. D. Kuchta, “Introduction to Cancer Chemotherapeutics,” Chemical Reviews, vol. 109, pp. 2859-2861, 2009.
[3] A. Jemal, F. Bray, M. M. Center, J. Ferlay, E. Ward, and D. Forman, “Global Cancer Statistics,” CA: A Cancer Journal for Clinicians, vol. 61, pp. 69-90, 2011.
[4] M. Arnold, M. S. Sierra, M. Laversanne, I. Soerjomataram, A. Jemal, and F. Bray, “Global Patterns and Trends in Colorectal Cancer Incidence and Mortality,” Gut, vol. 66, pp. 683-691, 2017.
[5] J. Veziant, R. Villéger, N. Barnich, and M. Bonnet, “Gut Microbiota as Potential Biomarker and/or Therapeutic Target to Improve the Management of Cancer: Focus on Colibactin-Producing Escherichia Coli in Colorectal Cancer,” Cancers, vol. 13, p. 2215, 2021.
[6] J. Kim and H. K. Lee, “Potential Role of the Gut Microbiome in Colorectal Cancer Progression,” Frontiers in Immunology, vol. 12, p. 807648, 2022.
[7] C. V. Olovo, X. Huang, X. Zheng, and M. Xu, “Faecal Microbial Biomarkers in Early Diagnosis of Colorectal Cancer,” Journal of Cellular and Molecular Medicine, vol. 25, pp. 10783-10797, 2021.
[8] N. A. Abdulmuttaleb, M. Q. Mohammed, and O. A. Mohsein, “Exploring the Connection Between Inflammatory Cytokines, Hypertension, and Diabetes in Angina Patients,” Cytokines, vol. 14, no. 15, p. 16, 2024.
[9] C. A. Dinarello, “Historical Insights Into Cytokines,” European Journal of Immunology, vol. 37, pp. 34-45, 2007.
[10] M. D. Turner, B. Nedjai, T. Hurst, and D. J. Pennington, “Cytokines and Chemokines: At the Crossroads of Cell Signaling and Inflammatory Disease,” Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol. 1843, pp. 2563-2582, 2014.
[11] K. Ozaki and W. J. Leonard, “Cytokine and Cytokine Receptor Pleiotropy and Redundancy,” Journal of Biological Chemistry, vol. 277, pp. 29355-29358, 2002.
[12] A. A. Hamad, H. M. Mustafa, and O. A. Mohsein, “Detection of the Levels of Immune Cytokines (IL-4, IL-5, TNF-α) in School-Age and Preschoolers With an Ascaris Lumbricoides Infection,” Journal of Parasitic Diseases, vol. 2024, pp. 1–6.
[13] T. G. Dinan, “Hypothalamic-Pituitary-Gut Axis Dysregulation in Irritable Bowel Syndrome: Plasma Cytokines as a Potential Biomarker?,” Gastroenterology, vol. 130, pp. 304-311, 2006.
[14] W. W. Lin and M. Karin, “A Cytokine-Mediated Link Between Innate Immunity, Inflammation, and Cancer,” Journal of Clinical Investigation, vol. 117, pp. 1175-1183, 2007.
[15] T. Ashizawa, “Clinical Significance of Interleukin-6 (IL-6) in the Spread of Gastric Cancer: Role of IL-6 as a Prognostic Factor,” Gastric Cancer, vol. 8, pp. 124-131, 2005.
[16] J. W. Yun, “A Novel Type of Blood Biomarker: Distinct Changes of Cytokine-Induced STAT Phosphorylation in Blood T Cells Between Colorectal Cancer Patients and Healthy Individuals,” Cancers, vol. 11, p. 1157, 2019.
[17] A. E. R. Kartikasari, “Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis,” Frontiers in Oncology, vol. 11, p. 692142, 2021.
[18] T. Koizumi, V. Shetty, and M. Yamaguchi, “Salivary Cytokine Panel Indicative of Non-Small Cell Lung Cancer,” Journal of International Medical Research, vol. 46, no. 9, pp. 3570-3582, 2018.
[19] H. S. Abd-Alwahab, Z. M. Farhan, and N. Ahmed, “Estimation of Thyroid Hormone and Adipocytokine Levels in Men With Obesity and Type 2 Diabetes in Thi-Qar Governorate.”
[20] D. T. Teachey, “Identification of Predictive Biomarkers for Cytokine Release Syndrome After Chimeric Antigen Receptor T-Cell Therapy for Acute Lymphoblastic Leukemia,” Cancer Discovery, vol. 6, no. 6, pp. 664-679, 2016.
[21] Y. Qian, W. Jia, and H. Liu, “Biomarkers and Immunotherapy of Hepatic-Biliary-Pancreatic Cancers,” Frontiers in Oncology, vol. 13, p. 1301416, 2023.
[22] K. Sanchez, “Multiplex Immunofluorescence to Measure Dynamic Changes in Tumor-Infiltrating Lymphocytes and PD-L1 in Early-Stage Breast Cancer,” Breast Cancer Research, vol. 23, p. 1, 2021.
[23] Y. Cui, “Body Mass and Stage of Breast Cancer at Diagnosis,” International Journal of Cancer, vol. 98, no. 2, pp. 279-283, 2002.
[24] P. H. Liu, “Association of Obesity With Risk of Early-Onset Colorectal Cancer Among Women,” JAMA Oncology, vol. 5, no. 1, pp. 37-44, 2019.
[25] M. Vij, “Clinicopathological Characteristics of Neutrophil-Rich Hepatocellular Carcinoma: An Uncommon Subtype of Primary Liver Cancer,” International Journal of Surgical Pathology, vol. 2024, p. 10668969241291882.
[26] J. W. Yang, C. Liang, and L. Yang, “Advancements in the Diagnosis and Treatment of Renal Epithelioid Angiomyolipoma: A Narrative Review,” Kaohsiung Journal of Medical Sciences, vol. 38, no. 10, pp. 925-932, 2022.
[27] D. Crosby, “Early Detection of Cancer,” Science, vol. 375, no. 6586, p. 9040, 2022.
[28] S. Zhou, H. Lu, and M. Xiong, “Identifying Immune Cell Infiltration and Effective Diagnostic Biomarkers in Rheumatoid Arthritis by Bioinformatics Analysis,” Frontiers in Immunology, vol. 12, p. 726747, 2021.
[29] G. Xue, “Characteristics of Immune Cell Infiltration and Associated Diagnostic Biomarkers in Ulcerative Colitis: Results From Bioinformatics Analysis,” Bioengineered, vol. 12, no. 1, pp. 252-265, 2021.
[30] W. Shao, “The Pyroptosis-Related Signature Predicts Prognosis and Indicates Immune Microenvironment Infiltration in Gastric Cancer,” Frontiers in Cell and Developmental Biology, vol. 9, p. 676485, 2021.
[31] Rašková, “The Role of IL-6 in Cancer Cell Invasiveness and Metastasis—Overview and Therapeutic Opportunities,” Cells, vol. 11, no. 22, p. 3698, 2022.
[32] E. J.-L. Dikova and J. Bagan, “Potential Non-Invasive Biomarkers for Early Diagnosis of Oral Squamous Cell Carcinoma,” Journal of Clinical Medicine, vol. 10, no. 8, p. 1658, 2021.
